Explore more
Trump, pharma
Digest more
President Trump announced a plan to reduce prescription drug prices by implementing a most-favored-nation policy with the pharmaceutical industry. The goal of the policy is for Americans to pay prices that are equal to or lower than what the pharmaceutical companies charge in other countries.
President Trump's executive order on drug pricing caused a surprising rally in pharmaceutical stocks. Read my analysis of PJP ETF.
The package revives President Donald Trump’s much-maligned Most Favored Nations rule but goes further into the private markets and beyond, leveraging the patent system, drug importation and more.
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries.
A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include Eli Lilly, which in February set out plans for $27bn of investment, while Johnson & Johnson said in March that it would invest more than $55bn in four factories.
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.
The revolutionary GLP-1 class of weight loss drugs are racking up blockbuster sales at a pace rarely seen in the pharmaceutical industry. But the pharma industry’s gain is the food industry’s loss.Approved for weight loss by the Food and Drug Administration just four years ago,
Feedback